1. Home
  2. SLRX vs EAD Comparison

SLRX vs EAD Comparison

Compare SLRX & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRX
  • EAD
  • Stock Information
  • Founded
  • SLRX N/A
  • EAD 2003
  • Country
  • SLRX United States
  • EAD United States
  • Employees
  • SLRX N/A
  • EAD N/A
  • Industry
  • SLRX Biotechnology: Pharmaceutical Preparations
  • EAD Finance/Investors Services
  • Sector
  • SLRX Health Care
  • EAD Finance
  • Exchange
  • SLRX Nasdaq
  • EAD Nasdaq
  • Market Cap
  • SLRX 1.8M
  • EAD 406.6M
  • IPO Year
  • SLRX N/A
  • EAD N/A
  • Fundamental
  • Price
  • SLRX $0.89
  • EAD $7.12
  • Analyst Decision
  • SLRX
  • EAD
  • Analyst Count
  • SLRX 0
  • EAD 0
  • Target Price
  • SLRX N/A
  • EAD N/A
  • AVG Volume (30 Days)
  • SLRX 3.5M
  • EAD 178.9K
  • Earning Date
  • SLRX 08-08-2025
  • EAD 01-01-0001
  • Dividend Yield
  • SLRX N/A
  • EAD 8.91%
  • EPS Growth
  • SLRX N/A
  • EAD N/A
  • EPS
  • SLRX N/A
  • EAD N/A
  • Revenue
  • SLRX N/A
  • EAD N/A
  • Revenue This Year
  • SLRX N/A
  • EAD N/A
  • Revenue Next Year
  • SLRX N/A
  • EAD N/A
  • P/E Ratio
  • SLRX N/A
  • EAD N/A
  • Revenue Growth
  • SLRX N/A
  • EAD N/A
  • 52 Week Low
  • SLRX $0.45
  • EAD $5.69
  • 52 Week High
  • SLRX $7.20
  • EAD $6.81
  • Technical
  • Relative Strength Index (RSI)
  • SLRX 49.85
  • EAD 78.09
  • Support Level
  • SLRX $0.86
  • EAD $6.83
  • Resistance Level
  • SLRX $1.33
  • EAD $7.18
  • Average True Range (ATR)
  • SLRX 0.14
  • EAD 0.04
  • MACD
  • SLRX -0.01
  • EAD 0.02
  • Stochastic Oscillator
  • SLRX 38.70
  • EAD 90.00

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

Share on Social Networks: